Rhumbline Advisers Eledon Pharmaceuticals, Inc. Transaction History
Rhumbline Advisers
- $113 Billion
- Q2 2025
A detailed history of Rhumbline Advisers transactions in Eledon Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 56,050 shares of ELDN stock, worth $153,016. This represents 0.0% of its overall portfolio holdings.
Number of Shares
56,050Holding current value
$153,016% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ELDN
# of Institutions
86Shares Held
36.8MCall Options Held
48.5KPut Options Held
30.3K-
Bvf Inc San Francisco, CA6.29MShares$17.2 Million0.67% of portfolio
-
Ra Capital Management, L.P. Boston, MA3.57MShares$9.74 Million0.21% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.32MShares$9.06 Million0.0% of portfolio
-
First Light Asset Management, LLC Edina, MN2.6MShares$7.1 Million1.08% of portfolio
-
Sphera Funds Management Ltd. Tel Aviv, L31.96MShares$5.35 Million1.46% of portfolio
About Eledon Pharmaceuticals, Inc.
- Ticker ELDN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 13,756,800
- Market Cap $37.6M
- Description
- Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that i...